Tim Harried

Tim Harried

Tim’s Company

Pfizer

Founded: 1848

Website: http://www.pfizer.com

Twitter: @pfizer_news

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company applies science and its global resources to improve health ... More » Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company applies science and its global resources to improve health and well-being at every stage of life. Pfizer’s diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many consumer health care products. The Company operates in two business segments: Biopharmaceutical and Diversified. Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units. Diversified includes Animal Health products that prevent and treat diseases in livestock and companion animals, and Consumer Healthcare products. On October 15, 2009, the Company completed its acquisition of Wyeth. In December 2009, Durata Therapeutics, Inc. acquired Vicuron Pharmaceuticals from Pfizer. Pfizer, Inc. is an American multinational pharmaceutical corporation headquartered in New York City, and with its research headquarters in Groton, Connecticut, United States. It is one of the world’s largest pharmaceutical companies by revenues. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. Pfizer’s products include Lipitor (atorvastatin, used to lower LDL blood cholesterol); Lyrica (pregabalin, for neuropathic pain/fibromyalgia); Diflucan (fluconazole, an oral antifungal medication); Zithromax (azithromycin, an antibiotic); Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib, an anti-inflammatory drug). Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals. Pfizer’s discovery of Terramycin (oxytetracycline) in 1950 put it on a path towards becoming a research-based pharmaceutical company. Pfizer has made numerous acquisitions, including of Warner–Lambert in 2000, Pharmacia in 2003 and Wyeth in 2009, the latter acquired for US$68 billion. Pfizer is listed on the New York Stock Exchange and its shares have been a component of the Dow Jones Industrial Average since April 8, 2004. [ CrunchBase ]

FoodBev.com | News | Chr Hansen makes regional structure changes

Chr. Hansen A/S - In addition to the executive board members, Cees de Jong, Klaus Pedersen, Knud Vindfeldt, Henrik Dalbøge, Carsten Bennike and Jesper Allentoft, the corporate leadership team will consist of Winnie Büegel (compliance), Christian Barker (strategic development) and the new group vice ...

Henrik Dalbøge

Mentioned in this article:
Henrik Dalbøge

Sky News Australia

Pfizer - Pfizer chief executive Ian Read cited several upcoming clinical reports that are being closely watched on Wall Street, including for palbociclib for treatment of advanced breast cancer and bococizumab for cholesterol reduction. 'We enter 2014 with confidence in the competitive ...

Ian Read

Mentioned in this article:
Ian Read

In Chase of a Blockbuster Cholesterol Drug - Drugs.com MedNews

The company does not have an anticipated launch date, said Pfizer spokesman MacKay Jimeson. (c)2013 Ventura County Star (Camarillo, Calif.) Visit Ventura County Star (Camarillo, Calif.) at www.vcstar.com ...

MacKay Jimeson

Mentioned in this article:
MacKay Jimeson

Analysis: Doctors worry as heart drug research loses steam | Reuters

Pfizer - " So far, however, working out how to target heart drugs effectively has proved elusive - a fact that has not been lost on investors in emerging medical technologies, according to Briggs Morrison, head of global medicines development at AstraZeneca, which is investing in both areas. "If ...

Briggs Morrison

Mentioned in this article:
Briggs Morrison

Zoetis Inc. research and development Kalamazoo headquarters remain crucial to company, says CEO | M...

Catherine Knupp serves as the Executive Vice President and President of Research and Development at Zoetis and leads operations in Kalamazoo, as she did under Pfizer since 2005. While company changes have led to the creation of some career development opportunities, Alaix says the spin ...

Catherine Knupp

Mentioned in this article:
Catherine Knupp

NJ’s Pain is NY’s Gain as Roche Christens Manhattan Collaboration Hub | Xconomy

Pfizer - Roche’s new Manhattan center will be headed by Judith Dunn, who has held positions in the commercial and research divisions of Pfizer. The center’s opening continues some momentum for Manhattan’s life sciences ecosystem. The Alexandria Center for Life Science already houses labs for ...

Judith Dunn

Mentioned in this article:
Judith Dunn

Study: Chantix Helps Smokers With Depression Quit Smoking - Drugs.com MedNews

Pfizer - Additional contributors to the study include Chad Morris, PhD, University of Colorado, Anschutz Medical Campus; and Tanya S. Ramey, MD, PhD, Sarah J. Dubrava, MS, Kostas Tsilkos, MD, Christina Russ, MD, and Carla Yunis, MD, MPH, of Pfizer...

Carla Yunis

Mentioned in this article:
Carla Yunis

NZ dollar little changed after RBA minutes | Scoop News

Pfizer - “The RBA minutes were pretty much in line with the previous minutes,” said Mark Johnson, senior client adviser at OM Financial in Wellington. “The Aussie dollar did fall off and helped drag the kiwi down with it.” Investors are keenly awaiting the results of this week’s Federal Open ...

Mark Johnson

Mentioned in this article:
Mark Johnson

Quebec Network for Personalized Health Care (QNPHC) | Media Advisory - Quebec Network for Personaliz...

During this event the following persons will speak: Mr. Bernard Prigent - Vice-President and medical director, Pfizer Canada, Chairman of the external Advisory Committee of the Quebec Network for Personalized Health Care Media representatives are invited to meet the members of this ...

Bernard Prigent

Mentioned in this article:
Bernard Prigent

Reforming medical research: Some progress, but huge obstacles remain | MinnPost

Pfizer - Pfizer CEO Ian Read said — with no shred of irony — that the Academic Detailing project is a waste of public money, because government has a “conflict of interest” when it disseminates evidence to clinicians. Despite all these problems (and what I’ve included here is only a sampling of ...

Ian Read

Mentioned in this article:
Ian Read

Join Newsle to find out when Tim Harried makes the news.

As a Newsle member, you’ll be able to:

  • Get alerts on Tim Harried
  • See news articles & blog posts about Tim Harried
  • Follow your friends & colleagues in the news
This profile only includes publicly available information. Questions or comments? Contact Us
Freebase CC-BY
Data from Freebase, licensed under CC-BY
Source: CrunchBase
Data from Wikipedia, licensed under the GFDL